Page 18 of articles about prrs
Dealing with PRRSv-positive breeding herds
Is the right strategy to get a farm stable, that is, control clinical signs reducing the economic impact of the disease; or should a farm adopt strategies to go “negative”? As for other questions in the epidemiological field, our answer is “it depends”.
Chile: current PRRS strain has no relation with the strain eradicated in 2007
PRRS Diagnosis and Monitoring Workshop
On October 17-19, 2013 the final meeting of the project "Understanding and fighting PRRS in Europe" (COST action FA0902) focused on the diagnosis and the monitoring of PRRS was held in Greece.
United States: Ohio forms first PRRS task force
Reoccurrence of PRRS in Chile
PRRS virus elimination: How to prove herd negativity?
One of the challenges when conducting a disease elimination project is to ensure that the pathogen has in deed been eliminated from the herd.
Genomics and pig health
One of the greatest long-term potentials for genomic selection is to identify specific genes or genomic regions with a significant impact on pig health and to aid selection for disease resistance and/or disease tolerance.
Ohio State researcher develops innovative vaccine for profit-draining swine virus
Vaccination against PRRSV: a practical approach
In general terms, immunization through vaccination is the easiest and safest way to stabilize a herd.
Effect of sample collection material on the detection of PRRSV in oral fluid
An intact sialoadhesin (Sn/SIGLEC1/CD169) is not required for attachment/internalization of the porcine reproductive and respiratory syndrome virus (PRRSV)
PRRSV: Interaction with other respiratory pathogens
PRRSV by itself may induce mild-to-severe respiratory disease but rarely results in mortality.
Assessment of the economic impact of PRRS virus on United States pork producers
PRRS Immunology
Resolving the basis of viral and host variation will require identification and characterization of key B- and T-cell epitopes conserved among diverse PRRSV, and of the molecular and structural details of key effector antibodies, T-cell antigen receptors, and MHC molecules that mediate broad, cross-protective immunity.